Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months

Tanimoto S, 2007, Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials., Catheter Cardiovasc Interv., 70, 515, 10.1002/ccd.21136

Onuma Y, 2011, Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent., Catheter Cardiovasc Interv., 78, 3, 10.1002/ccd.22864

Serruys PW, 2010, Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes., Circulation., 122, 2301, 10.1161/CIRCULATIONAHA.110.970772

Waksman R., 2006, Biodegradable stents: they do their job and disappear., J Invasive Cardiol., 18, 70

Oberhauser JP, 2009, Design principles and performance of bioresorbable polymeric vascular scaffolds., EuroIntervention., 5, F15, 10.4244/EIJV5IFA3

Onuma Y, 2010, Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial., EuroIntervention., 6, 447, 10.4244/EIJ30V6I4A76

Serruys PW, 2011, Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes., J Am Coll Cardiol., 58, 1578, 10.1016/j.jacc.2011.05.050

Brugaletta S, 2012, Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque?, Atherosclerosis., 221, 106, 10.1016/j.atherosclerosis.2011.12.008

Ormiston JA, 2012, First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study., Circ Cardiovasc Interv., 5, 620, 10.1161/CIRCINTERVENTIONS.112.971549

Wu HC, 2003, Monitoring the degradation process of biopolymers by ultrasonic longitudinal wave pulse-echo technique., Biomaterials., 24, 3871, 10.1016/S0142-9612(03)00135-2

Brugaletta S, 2012, Vascular compliance changes of the coronary vessel wall after bioresorbable vascular scaffold implantation in the treated and adjacent segments., Circ J., 76, 1616, 10.1253/circj.CJ-11-1416

Serruys PW, 2009, A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods., Lancet., 373, 897, 10.1016/S0140-6736(09)60325-1

Serruys PW, 2012, From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade?, Eur Heart J., 33, 16, 10.1093/eurheartj/ehr384

Okamura T, 2010, In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial., EuroIntervention., 5, 932, 10.4244/EIJV5I8A157

Mintz GS, 2001, American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents., J Am Coll Cardiol., 37, 1478, 10.1016/S0735-1097(01)01175-5

Tanimoto S, 2008, Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology., J Am Coll Cardiol., 52, 1616, 10.1016/j.jacc.2008.08.024

Bruining N, 2010, Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study., JACC Cardiovasc Interv., 3, 449, 10.1016/j.jcin.2010.02.004

Nair A, 2002, Coronary plaque classification with intravascular ultrasound radiofrequency data analysis., Circulation., 106, 2200, 10.1161/01.CIR.0000035654.18341.5E

Nair A, 2007, Automated coronary plaque characterisation with intravascular ultrasound backscatter: ex vivo validation., EuroIntervention., 3, 113

Shin ES, 2011, Assessment of the serial changes of vessel wall contents in atherosclerotic coronary lesion with bioresorbable everolimus-eluting vascular scaffolds using Shin’s method: an IVUS study., Int J Cardiovasc Imaging., 27, 931, 10.1007/s10554-010-9739-4

Shin ES, 2012, Reproducibility of Shin’s method for necrotic core and calcium content in atherosclerotic coronary lesions treated with bioresorbable everolimus-eluting vascular scaffolds using volumetric intravascular ultrasound radiofrequency-based analysis., Int J Cardiovasc Imaging., 28, 43, 10.1007/s10554-010-9779-9

Sihan K, 2009, Fully automatic three-dimensional quantitative analysis of intracoronary optical coherence tomography: method and Validation., Catheter Cardiovasc Interv., 74, 1058, 10.1002/ccd.22125

Prati F, 2010, Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis., Eur Heart J., 31, 401, 10.1093/eurheartj/ehp433

Gonzalo N, 2009, Optical coherence tomography assessment of the acute effects of stent implantation on the vessel wall: a systematic quantitative approach., Heart., 95, 1913, 10.1136/hrt.2009.172072

Regar E, 2007, Optical Coherence Tomography in Cardiovascular Research., London, UK: Informa Healthcare

Gonzalo N, 2009, Quantitative ex vivo and in vivo comparison of lumen dimensions measured by optical coherence tomography and intravascular ultrasound in human coronary arteries., Rev Esp Cardiol., 62, 615, 10.1016/S0300-8932(09)71328-4

Gomez-Lara J., 2011, A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds., Eur Heart J., 32, 294, 10.1093/eurheartj/ehq458

Gomez-Lara J., 2011, Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography., JACC Cardiovasc Interv., 4, 992, 10.1016/j.jcin.2011.03.020

Onuma Y., 2011, Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization?, Circulation., 123, 779, 10.1161/CIRCULATIONAHA.110.971606

Tsuchida K, 2007, Two-year serial coronary angiographic and intravascular ultrasound analysis of in-stent angiographic late lumen loss and ultrasonic neointimal volume from the TAXUS II trial., Am J Cardiol., 99, 607, 10.1016/j.amjcard.2006.09.107

Littell RC, 2006, SAS for Mixed Models., 2nd edition ed: SAS Institute

Cutlip DE, 2007, Clinical end points in coronary stent trials: a case for standardized definitions., Circulation., 115, 2344, 10.1161/CIRCULATIONAHA.106.685313

Sheehy A, 2012, In vivo characterisation of bioresorbable vascular scaffold strut interfaces using optical coherence tomography with Gaussian line spread function analysis., EuroIntervention., 7, 1227, 10.4244/EIJV7I10A195

Sarno G, 2010, IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process., Catheter Cardiovasc Interv., 75, 914, 10.1002/ccd.22332

Okamura T, 2011, First-in-man evaluation of intravascular optical frequency domain imaging (OFDI) of Terumo: a comparison with intravascular ultrasound and quantitative coronary angiography., EuroIntervention., 6, 1037, 10.4244/EIJV6I9A182

Ertl G, 2001, Anti-ischemic potential of drugs related to the renin-angiotensin system., J Cardiovasc Pharmacol., 37, S11, 10.1097/00005344-200109011-00003

Camm AJ., 2009., The ESC textbook of cardiovascular medicine. 2nd revised edition, ed. Oxford: Oxford University Press

Claessen BE, 2009, Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial., Circ Cardiovasc Interv., 2, 339, 10.1161/CIRCINTERVENTIONS.108.831800.108.831800

Diletti R, 2012, ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design., Am Heart J., 164, 654, 10.1016/j.ahj.2012.08.010